Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • ATVB Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Cover Art Award
    • ATVB Early Career Award
    • ATVB in Focus
    • Recent Brief Reviews of ATVB
    • Lecture Series
    • Collections
    • Recent Highlights of ATVB
    • Commentaries
    • Browse Abstracts
    • Insight into ATVB Authors
  • Resources
    • Instructions for Authors
    • Online Submission/Peer Review Site
    • Council on ATVB
    • Permissions and Rights Q&A
    • AHA Guidelines and Statements
    • Customer Service and Ordering Information
    • Author Reprints
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • LinkedIn
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Arteriosclerosis, Thrombosis, and Vascular Biology

  • My alerts
  • Sign In
  • Join

  • Facebook
  • LinkedIn
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • ATVB Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Cover Art Award
    • ATVB Early Career Award
    • ATVB in Focus
    • Recent Brief Reviews of ATVB
    • Lecture Series
    • Collections
    • Recent Highlights of ATVB
    • Commentaries
    • Browse Abstracts
    • Insight into ATVB Authors
  • Resources
    • Instructions for Authors
    • Online Submission/Peer Review Site
    • Council on ATVB
    • Permissions and Rights Q&A
    • AHA Guidelines and Statements
    • Customer Service and Ordering Information
    • Author Reprints
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Poster Abstract Presentations

Abstract 443: ABCA1 Up-Regulation but Not CETP Inhibition is Predicted to Increase the Reverse Cholesterol Transport (RCT) Input Rate: a Simulation Study of HDL-C Raising Targets Using a Novel in-silico Model of Lipoprotein Metabolism and Kinetics

James Lu, M. Nazeem Nanjee, Eliot A Brinton, Katrin Hübner, Norman A Mazer
Arteriosclerosis, Thrombosis, and Vascular Biology. 2013;33:A443
James Lu
Clinical Pharmacology, F. Hoffmann - La Roche Ltd., Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Nazeem Nanjee
Div of Cardiovascular Genetics, Univ of Utah, Salt Lake City, UT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eliot A Brinton
Atherometabolic Rsch, Utah Foundation for Biomedical Rsch, Salt Lake City, UT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katrin Hübner
BioQuant, Univ of Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norman A Mazer
Clinical Pharmacology, F. Hoffmann - La Roche Ltd., Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics

Jump to

  • Article
  • Info & Metrics
  • eLetters
Loading

Abstract

Introduction HDL is believed to mediate RCT and hence lower CV risk. The recent failures of HDL-C raising drugs to improve CV outcomes raise questions on the link between HDL-C and RCT. We investigate the association between the two using an in-silico model.

Methods The model describes the cyclic process of αHDL maturation from lipid-poor ApoA-I (pre-β1) and the regeneration of pre-β1 from αHDL particles via remodeling processes (e.g., particle fusion, SRB1 and CETP mediated lipid transfers). RCT is a complex process initiated by cholesterol efflux into plasma. In our model we assume that the ABCA1-dependent loading of cholesterol onto pre-β1 is the main contributor to cholesterol efflux and quantify this as the RCT input rate. The model is calibrated to literature data on normal and CETP deficient subjects and validated with data on ABCA1 deficiency. Using a virtual population of n=359 subjects with low HDL-C, we simulate two target modulations, 80% CETP inhibition and 100% ABCA1 up-regulation, chosen to raise HDL-C by comparable amounts.

Results Table 1 shows that both target modulations increase HDL-C by approximately 50%. For ABCA1 up-regulation, this reflects an increased RCT input rate; while for CETP inhibition, the increase in HDL-C results from a decreased clearance rate. The model also predicts a larger increase in ApoA-I and a greater decrease in the pre-β1 level and fraction with ABCA1 up-regulation compared to CETP inhibition.

Conclusions The level of HDL-CE reflects the ratio of the RCT input rate to the clearance rate. Our in-silico model provides a tool for evaluating HDL-C raising targets in terms of their differential effects on the underlying metabolic processes.

Embedded Image

  • HDL-C
  • reverse cholesterol transport
  • in silico model
  • © 2013 by American Heart Association, Inc.
Back to top

Current Issue

Arteriosclerosis, Thrombosis, and Vascular Biology
April 2018, Volume 38, Issue 4
  • Table of Contents

Jump to

  • Article
  • Info & Metrics

Article Tools

  • Citation Tools
    Abstract 443: ABCA1 Up-Regulation but Not CETP Inhibition is Predicted to Increase the Reverse Cholesterol Transport (RCT) Input Rate: a Simulation Study of HDL-C Raising Targets Using a Novel in-silico Model of Lipoprotein Metabolism and Kinetics
    James Lu, M. Nazeem Nanjee, Eliot A Brinton, Katrin Hübner and Norman A Mazer
    Arteriosclerosis, Thrombosis, and Vascular Biology. 2013;33:A443, originally published October 20, 2015

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Arteriosclerosis, Thrombosis, and Vascular Biology.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Abstract 443: ABCA1 Up-Regulation but Not CETP Inhibition is Predicted to Increase the Reverse Cholesterol Transport (RCT) Input Rate: a Simulation Study of HDL-C Raising Targets Using a Novel in-silico Model of Lipoprotein Metabolism and Kinetics
    (Your Name) has sent you a message from Arteriosclerosis, Thrombosis, and Vascular Biology
    (Your Name) thought you would like to see the Arteriosclerosis, Thrombosis, and Vascular Biology web site.
  • Share on Social Media
    Abstract 443: ABCA1 Up-Regulation but Not CETP Inhibition is Predicted to Increase the Reverse Cholesterol Transport (RCT) Input Rate: a Simulation Study of HDL-C Raising Targets Using a Novel in-silico Model of Lipoprotein Metabolism and Kinetics
    James Lu, M. Nazeem Nanjee, Eliot A Brinton, Katrin Hübner and Norman A Mazer
    Arteriosclerosis, Thrombosis, and Vascular Biology. 2013;33:A443, originally published October 20, 2015
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Arteriosclerosis, Thrombosis, and Vascular Biology

  • About ATVB
  • Instructions for Authors
  • AHA CME
  • Meeting Abstracts
  • Permissions
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Contact the Editorial Office:
email: atvb@atvb.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured